Nesiritide compared with milrinone for cardiac surgery

Management of patients with low cardiac output syndromes is difficult. Current therapies (ie, inotropes) have associated adverse effects and have not been shown to impact clinical outcomes such as decreased mortality or length of stay. Patients unable to recover from low cardiac output states have e...

Full description

Saved in:
Bibliographic Details
Published inThe Annals of pharmacotherapy Vol. 41; no. 3; p. 502
Main Author Blais, Danielle M
Format Journal Article
LanguageEnglish
Published United States 01.03.2007
Subjects
3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors
Cardiac Output, Low - drug therapy
Cyclic Nucleotide Phosphodiesterases, Type 3
Humans
Milrinone - therapeutic use
Natriuretic Agents - therapeutic use
Natriuretic Peptide, Brain - therapeutic use
Phosphodiesterase Inhibitors - therapeutic use
Risk Assessment
Thoracic Surgery
Online AccessGet more information

Cover

More Information
Summary:Management of patients with low cardiac output syndromes is difficult. Current therapies (ie, inotropes) have associated adverse effects and have not been shown to impact clinical outcomes such as decreased mortality or length of stay. Patients unable to recover from low cardiac output states have end organ damage, increased lengths of stay, increased hospital costs, and readmissions. Nesiritide has been suggested as an alternative or adjunct medication to treat cardiac surgery patients. Recent trials have provided information on the effects of some of these agents on clinical outcomes including respiratory failure, length of stay, and mortality.
ISSN:1542-6270
DOI:10.1345/aph.1H656